Impact of atypical antipsychotics on quality of life in patients with schizophrenia

CNS Drugs

Volumn 18, Issue 13, 2004, Pages 877-893

  Awad, A George ^a,c   Voruganti, Lakshmi N P ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c HUMBER RIVER REGIONAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; REMOXIPRIDE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE; ZOTEPINE;

AGITATION; AKATHISIA; CHRONIC DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; DELUSION; DISABILITY; DISEASE COURSE; DISEASE EXACERBATION; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; DRUG TOLERABILITY; DYSPHORIA; ECONOMIC ASPECT; EMOTIONAL DISORDER; FUNCTIONAL ASSESSMENT; HALLUCINATION; HEALTH CARE COST; HEMATOLOGIC DISEASE; HOSPITALIZATION; HOSTILITY; HUMAN; MENTAL PATIENT; METHODOLOGY; MODEL; MOOD DISORDER; POPULATION RESEARCH; PRIORITY JOURNAL; PSYCHOSOCIAL WITHDRAWAL; QUALITATIVE ANALYSIS; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA; SELF CARE; SIDE EFFECT; SOCIAL PSYCHOLOGY; SPEECH DISORDER; SYMPTOM; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; ECONOMICS, PHARMACEUTICAL; HUMANS; MODELS, PSYCHOLOGICAL; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 10044247109     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200418130-00004     Document Type: Review

References (118)

1. Davies LM, Drummond MF. The economic burden of schizophrenia. Psychiart Bull 1990; 14: 522-55
2. Puech A, Fleurot O, Rein W. Amisulpride, an atypical antipsychotic in the treatment of acute episodes of schizophrenia: a dose ranging study vs haloperidol. Acta Psychiatr Scand 1998; 98: 65-72
3. Peuskens J, Bech P, Möller HJ, et al. Amisulpride vs risperidone in the treatment of acute exacerbations of schizophrenia. Psychiatry Res 1999; 88: 107-17
4. Lewander T, Westbergh S-E, Morrison D. Clinical profile of remoxipride: a combined analysis of a comparative double-blind multicentre trial program. Acta Psychiatr Scand 1990; 82 Suppl. 358: 92-8
5. Lapierre YD, Ancill R, Awad AG, et al. A dose-finding study with remoxipride in the acute treatment of schizophrenic patients. J Psychiatr Neurosci 1992; 17: 135-45
6. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-96
7. Lieberman JA, Safferman AZ, Pollack S, et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994; 151: 1744-52
8. Lindenmayer JP, Grochowski S, Mabugat L. Clozapine effects of positive and negative symptoms: a six month trial in treatment-refractory schizophrenics. J Clin Psychopharmacol 1994; 14: 201-4
9. Chouinard G, Jones B, Remington G, et al. A Canadian multicentre placebo controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13: 25-40
10. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151: 825-35
11. Peuskens J, and the Risperidone Study Group. Risperidone in the treatment of patients with chronic schizophrenia: a multinational, multicentre, double-blind, parallel group study vs haloperidol. Br J Psychiatry 1995; 166: 712-26
12. Beasley CM, Tollefson GD, Tran PV, et al. Olanzapine vs placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14: 111-23
13. Tollefson GD, Beasley CM, Tran PV, et al. Olanzapine vs haloperidol in the treatment of schizophrenia and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154: 457-65
14. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine vs risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997; 17: 407-18
15. Martin PT, Grebb GA, Schmitz PJ, et al. Efficacy and safety of sertindole in double-blind, placebo-controlled trials of schizophrenic patients [abstract]. Schizophr Res 1994; 11: 107
16. Daniel DG, Wozniak P, Mack RJ, et al. Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. Psychopharmacol Bull 1998; 34: 61-9
17. Arvantis LA, Miller BG, the Seroquel Trial-13 Study Group. Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997; 42: 233-46
18. van Kammen DP, Targum SD, Sebree TB. Switching antipsychotic medications. J Clin Psychiatry 1997; 58: 63-72
19. Small J, Hirsch S, Arvantis LA, et al. Quetiapine in patients with schizophrenia: a high and low dose double-blind comparison with placebo. Arch Gen Psychiatry 1997; 54: 549-57
20. Müller-Spahn F, Dieterle D, Ackenheil M. Clinical efficacy of zotepine in the treatment of negative symptoms: results of an open and a double-blind controlled trial [in German]. Fortscher Neurol Psychiatr 1991; 59 Suppl. 1: 30-5
21. Petit M, Raniwalla J, Tweed J, et al. A comparison of an atypical and typical antipsychotic, zotepine vs haloperidol in patients with acute exacerbation of schizophrenia: a parallel group double-blind trial. Psychopharmacol Bull 1996; 32: 81-7
22. Keck P, Buffenstein A, Ferguson J, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berl) 1998; 140: 173-84
23. Daniel DG, Zimbroff DL, Potkin SG, et al. Ziprasidone 40mg bid and 80mg bid in the acute exacerbation of schizophrenia and schizoaffective disorder: results of a six-week placebo controlled trial. Neuropsychopharmacology 1999; 20: 491-505
24. Carson WH, Lieberman J, Pigott T, et al. Aripiprazole vs placebo in the treatment of stable chronic schizophrenia [abstract]. 41st Annual Meeting of the American College of Neuropsychopharmacology; 2002 Dec 8-12; San Juan
25. Bourin MS, McQuade RD, Carson WH, et al. Aripiprazole for long-term maintenance treatment of schizophrenia [abstract]. 41st Annual Meeting of the American College of Neuropsychopharmacology; 2002 Dec 8-12; San Juan
26. Wagstaff AJ, Bryson HM. Clozapine. A review of its pharmacological properties and therapeutic use in patients with schizophrenia who are unresponsive to or intolerant of classical antipsychotic agents. CNS Drugs 1995; 4: 370-400
27. Foster RH, Goa KL. Risperidone. A pharmacoeconomic review of its use in schizophrenia. Pharmacoeconomics 1998; 14: 97-133
28. Fulton B, Goa KL. Olanzapine: a review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. CNS Drugs 1997; 53: 281-98
29. Gunasekara NS, Spencer CM. Quetiapine: a review of its use in schizophrenia. CNS Drugs 1998; 9: 325-40
30. Prakash A, Lamb HM. Zotepine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia. CNS Drugs 1998; 9: 153-75
31. Davis SR, Markham A. Ziprasidone. CNS Drugs 1997; 8: 153-62
32. Kerwin RW, Taylor D. New antipsychotics: a review of their current status and clinical practice. CNS Drugs 1996; 6: 71-82
33. Worrell GA, Marken P, Beckman S, et al. Atypical antipsychotic agents: a critical review. Am J Health Syst Pharm 2000; 57: 238-55
34. Awad AG, Voruganti LNP, Heslegrave RJ. The aims of antipsychotic medication: what are they and are they being achieved? CNS Drugs 1995; 4: 8-16
35. Fleishhacker W, Hummer M. Drug treatment of schizophrenia, achivements and future possibilities in optimising outcomes. In: Mallarkey G, editor. Managing schizophrenia. Auckland: Adis International, 1999: 19-34
36. Calman KC. Quality of life in cancer patients: a hypothesis. J Med Ethics 1984; 10: 124-7
37. Wood-Dauphinee S, Williams JI. Reintegration in normal living as a proxy to quality of life. J Chronic Dis 1987; 40: 491-502
38. Ware JE. Conceptualizing disease impact and treatment outcomes. Cancer 1984; 53: 2316-23
39. Awad AG, Voruganti LNP. Intervention research in psychosis: issues related to the assessment of quality of life. Schizophr Bull 2000; 26: 557-64
40. Heslegrave RJ, Voruganti LNP, Awad AG. The influence of neurocognitive deficits and symptoms on quality of life in schizophrenia. J Psychiatry Neurosci 1997; 22: 235-43
41. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996; 153: 321-30
42. Brekke JS, Kohrt B, Green MF. Neuropsychological functioning as a moderator of the relationship between psychosocial functioning and the subjective experience of self and life in schizophrenia. Schizophr Bull 2001; 27: 697-708
43. Awad AG, Voruganti LNP, Heslegrave RJ. Preliminary validation of a conceptual model to assess quality of life in schizophrenia. Qual Life Res 1997; 6: 21-6
44. Ritsner M, Ponizovoskya P, Endicott J, et al. Relatively small impact adverse events of antipsychotics on life satisfaction of schizophrenia patients: a naturalistic study. Eur Neuropsychopharmacol 2002; 12: 31-8
45. Awad AG, Voruganti LNP, Heslegrave RJ. Measuring quality of life in patients with schizophrenia. Pharmacoeconomics 1997; 11: 32-47
46. Jeste DV, Klausner M, Brecher M, et al. A clinical evaluation of risperidone in the treatment of schizophrenia: a 10-week open label multicentre trial. Psychopharmacology (Berl) 1997; 131: 239-47
47. Endicott J, Spitzer RL, Fleiss JL, et al. The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976; 33: 766-71
48. Heinrichs DW, Hanlon TE, Carpenter WT. The quality of life scale: an instrument for rating the schizophrenic deficit symptoms. Schizophr Bull 1984; 10: 388-98
49. Barcia D, Ayuso JL, Herraiz ML, et al. Calidad de vida en pacientes esquizofrenicos tratados con risperidona. An Psiquiatr 1996; 12: 403-12
50. Bobes J, Gutierrez M, Gibert J, et al. Quality of life in schizophrenia: long-term follow-up in 362 chronic Spanish schizophrenic outpatients undergoing risperidone maintenance treatment. Eur Psychiatry 1998; 13: 158-63
51. McHorney CA, Wate JE, Lu R, et al. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality scaling assumptions and reliability across diverse patient groups. Med Care 1994; 32: 40-66
52. Brescan DW, Ramirez LF. Effect of risperidone on quality of life [abstract]. Qual Life Res 1997; 6: 626
53. Lehman AF. Quality of life tool kit. Cambridge (MA): The Evaluation Centre, 1995
54. Heinsch M, Ludwig M, Bullinger M. Psychometrische Testung der; Muncher Lebensqualitats Dimensionen Liste (MLDL). In: Bullinger M, Ludwig M, von Steinbuche N, editors. Lebensqualitat bei Kardovaskularen Erkrankungen. Gottingen: Hogrefe, 1991: 73-90
55. Franz M, Lis S, Pluddemann K, et al. Conventional vs atypical neuroleptics: subjective quality of life in schizophrenia patients. Br J Psychiatry 1997; 170: 422-5
56. Tran PV, Hamilton SH, Kunz AJ, et al. Double-blind comparison of olanzapine vs risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997; 17: 407-18
57. Mahmoud RA, Engelhart LM, Oster G, et al. Risperidone vs conventional antipsychotics: a prospective randomized naturalistic effectiveness trial of outcomes in chronic schizophrenia. 36th Annual Meeting of the American College of Neuropsychopharmacology; 1997 Dec 8-12; Hawaii
58. Huybrechts K. Outcomes assessment in schizophrenia: methodological issues. Schizophr Rev 1996; 3 Suppl. 4: 2-3
59. Jette AM. Concepts of health and methodological issues in functional assessment. In: Granger CV, Gresham GE, editors. Functional assessments in rehabilitation medicine. Baltimore (MD): Williams and Wilkins, 1984
60. Mahmoud RA, Engelhart LM, Rothman M, et al. Assessment of symptoms affecting quality of life and patient satisfaction with antipsychotic drugs: new tools and insights from a trial of risperidone vs olanzapine [poster]. 37th Annual Meeting of the American College of Neuropsychopharmacol; 1998 Dec 14-18; San Juan
61. Awad AG. Quality of life issues in medicated schizophrenics: therapeutic and research implications. In: Shriqui C, Nasralla H, editors. Contemporary issues in the treatment of schizophrenia. Washington: American Psychiatric Press, 1995: 735-47
62. Tempier R, Pawliuk N. Influence of novel and conventional antipsychotic medication on subjective quality of life. J Psychiatry Neurosci 2001; 26: 131-6
63. Baker F, Intagliata J. Quality of life in the evaluation of community support systems. Eval Program Plann 1982; 5: 69-79
64. Voruganti LNP, Cortese L, Oyewumi L, et al. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side effects profile and impact on quality of life. Schizophr Res 2000; 43: 135-45
65. Voruganti LNP, Cortese L, Oyewumi L, et al. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr Res 2002; 57: 201-8
66. Hamilton SH, Revicki DA, Edgell ET, et al. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: results from a randomized clinical trial. Pharmacoeconomics 1999; 15: 469-80
67. Revicki DA, Ginduso LA, Hamilton SH, et al. Olanzapine vs haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. Qual Life Res 1999; 8: 417-26
68. Ho BC, Miller D, Nopoulos P, et al. A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. J Clin Psychiatry 1999; 60: 658-63
69. Naber D, Moritz S, Lambert M, et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res 2001; 50: 79-88
70. Meltzer HY, Burnett S, Bastani B, et al. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 1990; 41: 892-7
71. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk benefit assessment. Am J Psychiatry 1995; 152: 183-90
72. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 1995; 10 Suppl. 3: 133-8
73. Essock SM, Hargreaves WA, Covell NH, et al. Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacol Bull 1996; 32: 683-97
74. Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med 1997; 337: 809-15
75. Colonna L, Turjanski S, Dondey-Nouvel L. Amisulpride: long-terra efficacy and safety [abstract]. Eur Psychiatry 1998; 13: 309
76. Saleem P, Olie JP, Loo H. Social functioning quality of life in the schizophrenic patient: advantages of amisulpride. Int Clin Psychopharmacol 2002; 17: 1-8
77. Awad AG, Lapierre YD, Angus C, et al. Quality of life and response of negative symptoms in schizophrenia to haloperidol and the atypical antipsychotic remoxipride. J Psychiatry Neurosci 1997; 22: 244-8
78. Hellewell JS, Kalali AH, Langham SJ, et al. Patient satisfaction and acceptability of long-term treatment with quetiapine. Int J Psychiatry Clin Pract 1999; 3: 105-13
79. Voruganti LNP, Awad AG. Personal Evaluation of Transitions in Treatment (PETiT): a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia. Schizophr Res 2002; 56: 37-46
80. Awad AG, Voruganti LNP, Mackell JA, et al. Patient attitude after switch to ziprasidone from other antipsychotics [abstract]. 11th Congress at the Association of European Psychiatrists; 2002 May 4-8; Stockholm
81. Daniel DG, Weiden PJ, O'Sullivan R. Improvement in indices of health status in outpatients with schizophrenia, following a switch to ziprasidone from conventional antipsychotics, olanzapine or risperidone [abstract]. 13th European College of Neuropsychopharmacology Congress; 2000 Sep 9-13; Munich
82. Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophr Bull 1993; 19: 609-18
83. Van Putten T, May PRA. Subjective response as a predictor of outcome in pharmacotherapy. Arch Gen Psychiatry 1978; 35: 477-80
84. Van Putten T, May PRA, Murder SR. Subjective response to antipsychotic drugs. Res Gen Psychiatry 1981; 38: 187-90
85. Voruganti L, Awad AG. Neuroleptic dysphoria: toward a new synthesis. Psychopharmacology (Berl) 2004; 171 (2): 121-32
86. Hogan TP, Awad AG, Eastwood MR. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminate ability. Psychol Med 1983; 13: 177-83
87. Awad AG, Hogan TP. Early treatment events and prediction of response to neuroleptics in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 1985; 9: 585-8
88. Weiden PJ, Dixon L, Francis A, et al. Neuroleptic Non-compliance in Schizophrenia. In: Tamminga C, Schulz SC, editors. Advances in neuropsychiatry and psychopharmacology. Vol. 1. New York: Raven Press, 1991: 285-95
89. Naber D, Walther A, Kirche T, et al. Subjective effects of neuroleptics predict compliance in prediction of neuroleptic treatment outcome in schizophrenia. In: Gaebel W, Awad AG, editors. Concepts and methods. Heidelberg: Springer Verlag, 1994: 111-22
90. Awad AG, Voruganti LNP, Heslegrave RJ. Assessment of the patient's subjective experiences in acute neuroleptic treatment: implications for compliance and outcome. Int Clin Psychopharmacol 1996; 11 Suppl. 2: 55-60
91. Awad AG. Antipsychotic medications: compliance and attitudes towards treatment. Curr Opin Psychiatry 2004; 17: 75-80
92. Voruganti LNP, Heslegrave RJ, Awad AG. Neuroleptic dysphoria may be the missing link between schizophrenia and substance abuse. J Nerv Ment Dis 1997; 185: 463-5
93. Awad AG. Quality of life of schizophrenic patients on medications and implications for new drug trials. Hosp Community Psychiatry 1992; 43: 262-5
94. Awad AG, Hogan TP. Subjective response to neuroleptics and the quality of life: implications for treatment outcome. Acta Psychiatr Scand Suppl 1994; 89 (380): 27-32
95. MacIntosh E, Cheng S, Richeng S, et al. The relationship of symptoms and level of functioning in schizophrenia to general well-being and the quality of life scale. Acta Psychiatr Scand 2000; 102: 303-9
96. Larsen EB, Gerlach J. Subjective experience of treatment, sideeffects, mental state and quality of life in chronic schizophrenic outpatients treated with depot neuroleptics. Acta Psychiatr Scand 1996; 93: 381-8
97. Brownie S, Garaven J, Gervin M, et al. Quality of life in schizophrenia: insight and subjective response to neuroleptics. J Nerv Ment Dis 1998; 186: 74-8
98. Tollefson GD, Andersen SW. Should we consider mood disturbances in schizophrenia as an important determinant of quality of life? J Clin Psychiatry 1999; 60 Suppl. 5: 23-9
99. Lyness WH, Fiddel NM, More KE. Destruction of dopaminergic nerve terminals in nucleus accumbens: effect on d-amphetamine self-administration. Pharmacol Biol Behav 1979; 11: 552-6
100. Roberts DC, Corcoran ME, Fibiger HC. On the role of ascending catecholamenergic systems in intravenous self-administration of cocaine. Pharmacol Biochem Behav 1977; 6: 615-20
101. Voruganti LNP, Slomka P, Zabel P, et al. Subjective effects of AMPT-induced dopamine depletion in schizophrenia: correlation between dysphoric responses and striatal D2 binding ratios on SPECT-imaging. Neuropsychopharmacology 2001; 25: 642-50
102. de Haan L, Lavalaye J, Linszend D, et al. Subjective experience and striatal dopamine D2 receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. Am J Psychiatry 2000; 157: 1019-20
103. Awad AG, Voruganti LN. New antipsychotics, compliance, quality of life, and subjective tolerability: are patients better off? Can J Psychiatry 2004; 49 (5): 297-302
104. Awad AG, Voruganti LNP. Quality of life and new antipsychotics in schizophrenia: are patients better off? Int J Soc Psychiatry 1999; 45: 268-75
105. Awad AG, Voruganti LNP. The subjective/objective dichotomy in schizophrenia: relevance to nosology, research and management. In: Gaebel W, editor. Zukunftsperspektiven in Psychiatries Und Psychotherapie. Darmstadt: Steinkopff Verlag, 2002: 21-7
106. Hargreaves WA, Shumway M. Pharmacoeconomics of antipsychotic drug therapy. J Clin Psychiatry 1996; 57 Suppl. 9: 66-76
107. Revicki D. Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia. Schizophr Res 1999; 35: 101-9
108. Addington DE, Jones B, Bloom D, et al. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther 1993; 15: 917-26
109. Albright PS, Livingston S, Keegan DL, et al. Reduction of health care resource utilization and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy: a retrospective analysis using the Saskatchewan health linkage data bases. Clin Drug Invest 1996; 11: 289-99
110. Guest JF, Hart WM, Cookson RF, et al. Pharmacoeconomic evaluation of long-term treatment with risperidone for patients with chronic schizophrenia. Br J Med Econ 1996; 10: 59-67
111. Reid WH, Mason M, Toprac M. Savings in hospital bed-days related to treatment with clozapine. Hosp Community Psychiatry 1994; 45: 261-3
112. Dickson RA. Hospital days in dozapine-treated patients. Can J Psychiatry 1998; 43: 945-8
113. Zito JM. Pharmacoeconomics of the new antipsychotics for the treatment of schizophrenia. Psychiatric Clin North Am 1998; 21: 181-202
114. Awad AG, Voruganti LNP. Cost-utility analysis in schizophrenia. J Clin Psychiatry 1999; 60 Suppl. 3: 22-6
115. Voruganti LNP, Awad AG, Oyewumi LK. et al. Assessing health utilities in schizophrenia: a feasibility study. Pharmacoeconomics 2000; 17: 273-86
116. Karow A, Naber D. Subjective wellbeing and quality of life under atypical antipsychotic treatment. Psychopharmacology 2002; 162: 3-10
117. Ritsner M, Kurs R. Impact of antipsychotic agents and their side-effects on the quality of life in schizophrenia. Expert Rev Pharmacoeconomics Outcomes Res 2002; 2: 89-98
118. Awad AG. Antipsychotic medications in schizophrenia: how satisfied are our patients? In: Hellewell J, editor. Clear perspectives. Vol. 2. London: Shire Hall International,, 1999: 1-6